Safety and Efficacy of Overlapping Homogenous Drug-Eluting Stents in Patients with Acute Myocardial Infarction: Results from Korea Acute Myocardial Infarction Registry |
| |
Authors: | Khurshid Ahmed Myung Ho Jeong Rabin Chakraborty Young Joon Hong Doo Sun Sim Sumera Ahmed Seung Hwan Hwang Min Goo Lee Keun Ho Park Ju Han Kim Youngkeun Ahn Myeong Chan Cho Chong Jin Kim Young Jo Kim Jong Chun Park Jung Chaee Kang The Korea Acute Myocardial Infarction Registry Investigators |
| |
Affiliation: | 1The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.;2Department of Cardiology, Apollo Gleneagles Hospital, Kolkata, India.;3Department of Cardiology, Chungbuk National University Hospital, Cheongju, Korea.;4Department of Cardiology, East West Neo Medical Center, Seoul, Korea.;5Department of Cardiology, Yeungnam University Hospital, Daegu, Korea. |
| |
Abstract: | The aim of this study was to compare safety and efficacy of 4 homogenous overlapping drug-eluting stents (DES) in acute myocardial infarction (AMI) patients. We selected 1,349 consecutive patients (62.1 ± 14.9 yr, 69.4% male) who received homogenous overlapping DESs in diffuse de novo coronary lesions from Korea Acute Myocardial Infarction Registry from April 2006 through September 2010. They were divided into 4 groups based on type of DES implanted - Paclitaxel (PES), Sirolimus (SES), Zotarolimus (ZES) and Everolimus (EES)-eluting stents. Primary endpoint was 12-month MACE. We also studied EES versus other DESs (PES + SES + ZES). Mean stent length was 26.2 ± 7.5 mm and mean stent diameter was 3.1 ± 0.4 mm. Average number of stents used per vessel was 2.2 ± 0.5. Incidence of major adverse cardiac events (MACE) in PES, SES, ZES, and EES groups were 9.5%, 9.2%, 7.5%, and 3.8%, respectively (P = 0.013). In EES group, overall MACE and repeat revascularization were lowest, and no incidence of stent thrombosis was observed. Non-fatal MI was highest in PES, almost similar in SES and EES with no incidence in ZES group (P = 0.044). Cox proportional hazard analysis revealed no differences in the incidence of primary endpoint (P = 0.409). This study shows no significant differences in 12-month MACE among 4 groups. |
| |
Keywords: | Drug-Eluting Stents Myocardial Infarction Coronary Angioplasty |
|
|